Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study
Multicenter retrospective study finds interim PET response predicts survival in untreated CD5-positive DLBCL, suggesting treatment modifications may be necessary.
Key Points
The study aims to evaluate the efficacy of Pola-R-CHP as initial therapy for patients with CD5-positive diffuse large B-cell lymphoma.
Multicenter retrospective study of previously untreated CD5-positive DLBCL patients treated with Pola-R-CHP
Treatment response assessed by PET/CT after 3 cycles and at end of treatment
Study analyzed 32 patients with a median follow-up of 17.9 months.
Overall response rate (ORR) was 100% after 3 cycles, with a complete response rate (CRR) of 71.9%
At end of treatment, ORR and CRR were 93.8% and 75% respectively
Failure to achieve a complete response after 3 cycles predicted inferior survival (PFS HR: 18.1, p = 0.02; OS HR: 12.3, p = 0.033).